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INTRODUCTION
Patients with chronic obstructive pulmonary disease (COPD) and acute coronary syndromes (ACS) are a high-risk population with increased mortality rates [1] [2] [3] . Observational studies show that these patients undergo invasive tests less often and are treated less frequently with guideline-based secondary preventions, indicating a more conservative treatment approach with potentially detrimental effects on outcome [4] [5] [6] .
Limited evidence exists regarding outcome after cardiac surgery, especially coronary artery bypass grafting (CABG), in patients with COPD. CABG has increasingly become reserved for patients with more advanced coronary artery disease, in particular 3-vessel disease (3VD) and in cases involving the left main coronary artery (LMCA) [7] . The latest European Society of Cardiology revascularization guidelines recommend CABG as the revascularization strategy in patients with 3VD or LMCA involvement and stress that the appropriate revascularization strategy should be discussed by the Heart Team [8] .
Current available data suggest that COPD is associated with increased risk for patients having cardiac surgical procedures. COPD was common in a population who had surgical aortic valve replacement; long-term, but not short-term, survival was reduced in proportion to the severity of COPD [9] . Similarly, another study showed an association between increasing severity of COPD, respiratory complications and mortality rate in patients undergoing total arch replacement [10] . Another study on nonemergent CABG found a consistent association between increasing severity of COPD and postoperative complications, including early death [11] .
More studies on the risks associated with COPD in patients with ACS undergoing CABG are needed. The goal of the present study was to study the effect of COPD on perioperative complications and long-term mortality rates following CABG or percutaneous coronary intervention (PCI) only in patients with 3VD or LMCA lesions in a nationwide contemporary population with ACS.
METHODS

Nationwide registries
Patients were included from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) registry [12] . The SWEDEHEART registry has several components, including the Swedish Coronary Angiography and Angioplasty Registry, which covers all patients undergoing procedures in catheterization laboratories and cardiac surgery (Swedish Heart Surgery Registry). SWEDEHEART prospectively collects data on patient demographics and in-hospital parameters from coronary care units and catheterization laboratories and surgical characteristics from operating rooms and postoperative care units. The Swedish Heart Surgery Registry is connected to all 8 cardiothoracic surgery centres in Sweden. We enriched data on comorbidities, including COPD status (yes/no), from the National Patient Registry using International Classification of Disease (ICD) diagnosis codes linked to all previous hospitalizations and specialized outpatient visits [13] . The codes used to define COPD were ICD-9 = 491-492, 496 and ICD-10 = J41-J44. COPD status was also ascertained from the National Drug Dispensary registry, where dispensed prescriptions of certain medications for COPD [Anatomical Therapeutic Chemical codes: R03AK (Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics), R03BB01 (Ipratropium bromide) or R03BB04 (Tiotropium bromide)] in the previous 6 months before the event indicated COPD. A validity study on COPD diagnoses from the national patient registry found less than 10% misclassifications [14] . Data on vital status, time of death and cause of death were collected from the Swedish National Cause of Death Registry. Ascertainment of the underlying cause of death with this registry is uncertain due to suboptimal agreement between cause of death and the last known main diagnosis [15] . Data from the various registries were merged into a single database using the personal identification number unique to each Swedish citizen. We protected anonymity by replacing the personal identification number with a serial number. The study was approved by the regional ethical review board of the Karolinska Institute, Stockholm, Sweden.
Study design and end-point definitions
We included all patients presenting with ACS where the angiogram showed 3VD or LMCA involvement between 2006 and 2014 who underwent CABG in the first 30 days after the event or who had PCI only (Fig. 1) . Patients with a history of CABG were excluded. The study population was divided into 2 separate cohorts: the population who had CABG and the population who had PCI only. These cohorts were stratified by COPD status and compared with regard to outcome. The primary end-point was the 5-year, all-cause mortality rate. We also explored cardiovascular-related deaths from information provided in death certificates. Secondary end-points were 30-day mortality rate and in-hospital complications following CABG: reoperation due to bleeding, sternal insufficiency or mediastinitis, postoperative stroke, prolonged ventilator time, new-onset dialysis or atrial fibrillation and infections.
Statistical analyses
Continuous variables were expressed as medians and first to third quartiles. Categorical variables were expressed as counts and percentages. Differences in continuous variables between patients with COPD and those without COPD were assessed with the Mann-Whitney U-test. Differences between categorical variables were assessed with the v 2 test. Associations between age, sex, comorbidities and having CABG surgery versus PCI only were calculated with multivariable logistic regression. Mortality rates were calculated with the Kaplan-Meier estimator, and differences between the groups were calculated with the log-rank test. Univariable and multivariable hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated with the Cox proportional hazards model. For other in-hospital end-points, counts, percentages and odds ratios (ORs) with 95% CIs were calculated with univariable and multivariable logistic regression. Multivariable models were adjusted for age (3-knot restricted cubic spline), sex, smoking status (current smoker or not) and comorbidities (diabetes, hypertension, heart failure, previous myocardial infarction, previous stroke, previous PCI, peripheral artery disease and cancer within 2 years). The percentage of missing values within groups is reported in brackets for each variable whenever prevalent. All univariable and multivariable analyses were restricted to complete cases. There were no missing values in COPD status or covariates, but in a number of in-hospital outcome variables, missing data ranged from 0.4% (reoperation due to sternal insufficiency or mediastinitis) to 66.5% (pneumonia). The variables with missing data were often introduced at a later stage in the registry and therefore were not always available from the start of the inclusion period. All statistical analyses were performed using STATA (version 14.1, StataCorp, College Station, TX, USA). The study flow chart was prepared with draw.io (www.draw.io) (JGraph Ltd, London, UK). All P-values were two-tailed, and 0.05 was considered statistically significant.
RESULTS
Patient characteristics
There were 6985 patients in the CABG-treated population (COPD prevalence = 8.0%) and 14 209 in the PCI only population (COPD = 8.2%). In the CABG-treated population, patients with COPD versus those without COPD were older [median age 71 (65-76) vs 69 (62-75), P < 0.001], less often male, more often current smokers and to a higher extent burdened with several comorbidities (Table 1) . ST-segment elevation myocardial infarction was less prevalent in the COPD group (14.3% vs 18.6%, P = 0.011), as was PCI preceding CABG. Patients with COPD more often had LMCA involvement on the angiogram and a reduced left ventricular ejection fraction (52.3% vs 59.0%, P = 0.032). Also, patients with COPD had a longer in-hospital course following ACS (median days 10 vs 8, P < 0.001) and were less often given beta-blockers and statins when they were discharged from the hospital. Differences between patients with COPD versus those without COPD were similar in the population treated with PCI only, i.e. patients with COPD were older and had more comorbidities.
Surgical characteristics
The timing of surgery in relation to COPD status is shown in Fig. 2 and Table 2 . Patients with COPD less often underwent emergency CABG [defined as having surgery the same day as the event (2.2% vs 3.8%, P = 0.050)]. Patients with COPD had increased operative risk compared with patients without COPD (logistic EuroSCORE II 3% vs 2%, P < 0.001). They less often underwent on-pump surgery (97.5% vs 99.2%, P < 0.001). There were numerically fewer central and peripheral anastomoses in the COPD group.
Associations between age, sex, comorbidities and coronary artery bypass grafting COPD was not independently associated with a higher probability of either undergoing or being ruled out of CABG surgery (OR: 1.04, 95% CI = 0.94-1.17) ( Table 3) . Older age (80 years and above), female sex, current smoking, heart failure, previous PCI and cancer within 2 years were associated with a lower probability of undergoing CABG surgery, whereas diabetes, hypertension, previous myocardial infarction and chronic kidney disease Stage > _III were independently associated with a higher probability.
End-points
The primary end-point of the 5-year all-cause mortality rate occurred significantly more often in patients with COPD, both in the population treated with CABG (Kaplan-Meier event rates: 27.2% vs 14.5%, P < 0.001) and in those treated with PCI only (Kaplan-Meier event rates: 50.1% vs 29.1%, P < 0.001) (Fig. 3) .
After adjustments, COPD remained associated with a significantly higher 5-year mortality rate (CABG population HR: 1.52, 95% CI = 1.25-1.86, P < 0.001; PCI population HR: 1.44, 95% CI = 1.30-1.59, P < 0.001). The majority of deaths in the CABG population were of cardiovascular disease, and there were no significant differences between the groups (cardiovascular death in patients with COPD and without COPD: 50.4% vs 53.1%, P = 0.22). Two post-CABG in-hospital complications occurred significantly more often in patients with COPD: any infection in need of antibiotic treatment (OR: 1.48, 95% CI = 1.07-2.04, P = 0.017) and pneumonia (OR: 2.21, 95% CI = 1.39-3.52, P = 0.001) ( Table 4) . Several outcomes were numerically more common in the group with COPD. A 30-day landmark analysis that excluded patients who died during the first 30 days after surgery still showed that COPD was associated with an increased 5-year mortality rate (multivariable HR: 1.44, 95% CI 1.15-1.82, P = 0.002).
DISCUSSION
The main finding in the present large nationwide study was that patients with ACS and COPD and 3VD/LMCA disease had a substantially higher risk of death in the long term following CABG or PCI only, not explained by differences in age or comorbidities. The 30-day mortality rate after CABG was also higher, possibly a result of significantly more postoperative infections. COPD was not an independent determinant in the choice of the surgical revascularization strategy. The present study did not aim to compare CABG with PCI. The observed differences in outcome between the choice of revascularization strategy should be viewed as descriptive only. A large number of patients with COPD and severe coronary artery disease who are referred for PCI are deemed ineligible for surgery. Accordingly, no direct analyses comparing CABG with PCI only were performed, because the risk of residual confounding would be too large and therefore more adequately addressed in properly powered randomized controlled trials. Previous studies investigating the impact of COPD on post-CABG outcomes vary in size and design and show conflicting results. The seminal large multinational study behind the EuroSCORE risk model found chronic airway disease to be significantly associated with increased surgical mortality rates [16, 17] . A smaller study that investigated the impact of COPD on CABG outcome only found severe COPD to influence hospital deaths [18] . Another small case-control study looked into the impact of COPD on long-term mortality rates and a significantly higher long-term mortality rate in patients with COPD, while also stressing that those who underwent the procedure seemed to benefit from it [19] . In addition, Fuster et al. [20] found that preoperative forced expiratory volume in 1 s < _60%, but not COPD across the board, was significantly associated with increased in-hospital deaths. In contrast, Manganas et al. [21] did not find the presence, or the severity, of COPD to influence the 30-day mortality rates post-CABG but found an increased incidence of pulmonary infections and prolonged hospital stays in patients with severe COPD, in accordance with our results. The larger and more recent SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) trial randomized patients with 3VD or LMCA involvement to PCI or CABG and found COPD to be a highly influential correlate of the 4-year mortality rate (HR: 2.44, 95% CI 1.30-4.60), independent of age and other covariates [22] . Our study also found COPD to be an independent predictor of long-term mortality rates, but our effect estimate was lower (adjusted HR: 1.52, 95% CI 1.25-1.86). The majority of deaths in our patient population were estimated as cardiovascular, irrespective of COPD status. This finding reaffirms the large impact of cardiovascular disease in patients with COPD and stresses the importance of optimized cardiovascular care.
Our observational study is similar to the SYNTAX trial in that we investigated patients with 3VD or LMCA involvement undergoing CABG. Although the SYNTAX trial included allcomers, we restricted our selection to patients presenting with ACS. A diagnosis of COPD was not found to independently influence the revascularization strategy, indicating that clinicians may place more importance on other factors. Our findings regarding absolute mortality rates are similar to those of the SYNTAX trial (4-year mortality rate of 22.1% for patients with COPD compared with 5-year mortality rate of 27.2% in our study) and another study [23] .
The reason why patients with COPD seem to have worse outcomes following CABG is likely multifactorial, including a higher burden of comorbidities resulting in a more unstable presentation that warrants necessary stabilization before the patient undergoes the surgical procedure. This observation is supported by data from the analyses of timing to surgery, where patients with COPD seemed to be treated less frequently in the emergency setting, perhaps indicating that they were more often considered too unstable to head directly into the operating room. Additionally, patients with COPD had a greater risk of postoperative infections, likely contributing to both longer hospital stays and increased 30-day mortality rates. Clinicians should watch for early signs of infections and promptly treat these when indicated. We also found high surgical revision rates due to bleeding, irrespective of COPD status. A relatively large proportion of the patients with ACS in our study were treated preoperatively (in the preceding 0-5 days) with modern P2Y12 inhibitors, known to improve the outcome in ACS but to increase bleeding post-CABG [24] , and many were treated with PCI before CABG. These patients often received substantial amounts of anticoagulation medications in the catheterization laboratory, which likely contributed to the increased risk of bleeding complications post-CABG.
Limitations
This study has inherent limitations that merit consideration. First, COPD status was based on ICD diagnoses from many different clinicians and from dispensed prescriptions of COPD medications. Therefore, it is possible that the diagnostic criteria for COPD varied between cases and that some patients were incorrectly diagnosed. Second, we did not have pulmonary function estimates and were not able to stratify the analyses based on COPD severity. Third, inhospital complications post-CABG in the SWEDEHEART registry have never been validated and therefore included a measure of uncertainty; in some of these end-points, the number of missing values was high. Fourth, a logistic EuroSCORE II [25] was available only for a limited number of cases since it was first introduced in 2011. Lastly, even though we adjusted for known confounders, it is likely that unknown residual confounding remains; therefore, no definite conclusion of causality can be established, and the results should be viewed as hypothesis generating.
CONCLUSION
Patients with COPD presenting with ACS and 3VD/LMCA disease are a high-risk population following CABG or PCI only, with a higher risk of long-term and short-term deaths as well as postoperative infections. Preventive measures, including careful monitoring for signs of infection and prompt antibiotic treatment when indicated, should be considered.
